atezolizumab
Overall Survival Benefit Achieved With First-Line Checkpoint Inhibitor in High-Risk NSCLC
In patients with non-small cell lung cancer (NSCLC) ineligible for standard chemotherapy, a first-line checkpoint ...
NOVEMBER 9, 2022
FDA Approves Tecentriq as Adjuvant Rx for Stage II-IIIA NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) for adjuvant treatment after resection and platinum-based ...
OCTOBER 29, 2021
Checkpoint Inhibitor Shows Benefit for Early-Stage NSCLC
In patients with resected stage II to IIIA NSCLC who received cisplatin-based chemotherapy, atezolizumab reduced ...
AUGUST 2, 2021
FDA Grants New Indication for Tecentriq Plus Cotellic and Zelboraf for Advanced Melanoma
The new combination increased PFS to a median of 15.1 months compared with placebo plus cobimetinib and vemurafenib ...
AUGUST 4, 2020
FDA Approves Two Checkpoint Inhibitor Regimens for First-Line Metastatic NSCLC Treatment
The regimens were approved as first-line treatment for patients with metastatic NSCLC whose tumors express ...
MAY 20, 2020
Tecentriq + Chemo Approved for First-Line NSCLC Without EGFR/ALK Mutations
The FDA has approved atezolizumab (Tecentriq, Genentech) in combination with nab-paclitaxel (Abraxane, Celgene) and ...
DECEMBER 9, 2019
FDA Grants New Breast Cancer Indication for Genentech’s Tecentriq
The FDA granted a new indication for Tecentriq plus chemotherapy for the treatment of adults with unresectable ...
APRIL 1, 2019
Atezolizumab Combo Regimen Approved for ES-SCLC
Atezolizumab (Tecentriq, Genentech) is the first new treatment option for this type of lung cancer in more than 20 ...
MARCH 20, 2019
Tecentriq Combo Approved for First-Line Rx of Metastatic Nonsquamous NSCLC
The FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin, Genentech), ...
DECEMBER 19, 2018
FDA Modifies UC Indications of Pembrolizumab, Atezolizumab
The FDA modified the urethal cancer indications of Keytruda and Tecentriq, limiting their use to patients who are ...
JULY 9, 2018
FDA Warns of Decreased Survival in Some UC Patients on Keytruda or Tecentriq
The FDA issued an alert about decreased survival associated with the use of pembrolizumab (Keytruda, Merck) or ...
MAY 21, 2018
Combination Therapy Shows Promise in mRCC
The combination of atezolizumab (Tecentriq, Genentech) and bevacizumab (Avastin, Genentech) appears to be a ...
JUNE 28, 2017